Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.
Aim(s): We aimed to compare differences in progression free survival (PFS) and overall survival (OS) in patients treated with oral etoposide, short infusion and long infusion.
Materials and methods: Patients (n=236) from the Nordic NEC study were divided into three groups receiving etoposide as along infusion (24h, n=170), short infusion (<5h, n=33), or oral etoposide (n=33). PFS and OS were analyzed with Kaplan-Meier (estimated with log-rank statistics), cox proportional hazard ratios (HRs) and confidence intervals (CIs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Student Abir A Ali
Ali A A
, Grönberg M
, Hjortland G O
, Grønbæk H
, Ladekarl M
, Langer S W
, Welin S
, Vestermark L W
, Österlund P
, Knigge U
, Sørbye H
, Janson E T
To read results and conclusion, please login ...
Further abstracts you may be interested in